EP2026837A4 - Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations - Google Patents

Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations

Info

Publication number
EP2026837A4
EP2026837A4 EP07777355A EP07777355A EP2026837A4 EP 2026837 A4 EP2026837 A4 EP 2026837A4 EP 07777355 A EP07777355 A EP 07777355A EP 07777355 A EP07777355 A EP 07777355A EP 2026837 A4 EP2026837 A4 EP 2026837A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
production
methods
cell receptor
receptor mimics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07777355A
Other languages
German (de)
English (en)
Other versions
EP2026837A2 (fr
Inventor
Jon A Weidanz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RECEPTOR LOGIC INC.
Original Assignee
RECEPTOR LOGIC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/517,516 external-priority patent/US20070092530A1/en
Application filed by RECEPTOR LOGIC Inc filed Critical RECEPTOR LOGIC Inc
Publication of EP2026837A2 publication Critical patent/EP2026837A2/fr
Publication of EP2026837A4 publication Critical patent/EP2026837A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
EP07777355A 2006-06-01 2007-06-01 Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations Withdrawn EP2026837A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81007906P 2006-06-01 2006-06-01
US11/517,516 US20070092530A1 (en) 2004-05-27 2006-09-07 Antibodies as T cell receptor mimics, methods of production and uses thereof
PCT/US2007/012958 WO2007143104A2 (fr) 2006-06-01 2007-06-01 Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations

Publications (2)

Publication Number Publication Date
EP2026837A2 EP2026837A2 (fr) 2009-02-25
EP2026837A4 true EP2026837A4 (fr) 2010-06-02

Family

ID=40262722

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07777355A Withdrawn EP2026837A4 (fr) 2006-06-01 2007-06-01 Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations

Country Status (5)

Country Link
EP (1) EP2026837A4 (fr)
AU (1) AU2007254859A1 (fr)
CA (1) CA2656583A1 (fr)
IL (1) IL195470A0 (fr)
WO (1) WO2007143104A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262834A4 (fr) * 2008-02-27 2011-08-17 Receptor Logic Inc Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d utilisation
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
SG10201913247XA (en) 2015-10-23 2020-02-27 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2018083505A1 (fr) 2016-11-07 2018-05-11 Immunocore Limited Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (fr) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN109952319B (zh) 2016-06-02 2023-08-25 英美偌科有限公司 对gp100具有特异性的TCR-抗CD3 scFv融合蛋白的定量用药方案
CA3059753A1 (fr) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Produits de recombinaison chimeriques d'anticorps/recepteur des cellules t et leurs utilisations
US11485785B2 (en) 2017-06-14 2022-11-01 Adicet Bio, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020197672A1 (en) * 2000-10-10 2002-12-26 Hildebrand William H. Comparative ligand mapping from MHC positive cells
WO2003070752A2 (fr) * 2002-02-20 2003-08-28 Dyax Corporation Ligands de liaison au complexe mhc-peptide
WO2004011483A2 (fr) * 2002-07-31 2004-02-05 Ludwig Institute For Cancer Research Ssx-2 et peptides lies a ssx-2 isoles utiles comme liaison de l'antigene hla et epitopes de cellule t tueuse, et leurs utilisations
US20050003483A1 (en) * 2000-10-10 2005-01-06 Hildebrand William H. Comparative ligand mapping from MHC class 1 positive cells
WO2005116072A2 (fr) * 2004-05-27 2005-12-08 Weidanz Jon A Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation
WO2007030451A2 (fr) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020197672A1 (en) * 2000-10-10 2002-12-26 Hildebrand William H. Comparative ligand mapping from MHC positive cells
US20050003483A1 (en) * 2000-10-10 2005-01-06 Hildebrand William H. Comparative ligand mapping from MHC class 1 positive cells
WO2003070752A2 (fr) * 2002-02-20 2003-08-28 Dyax Corporation Ligands de liaison au complexe mhc-peptide
WO2004011483A2 (fr) * 2002-07-31 2004-02-05 Ludwig Institute For Cancer Research Ssx-2 et peptides lies a ssx-2 isoles utiles comme liaison de l'antigene hla et epitopes de cellule t tueuse, et leurs utilisations
WO2005116072A2 (fr) * 2004-05-27 2005-12-08 Weidanz Jon A Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation
WO2007030451A2 (fr) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANGLES V ET AL: "Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE LNKD- DOI:10.1007/S00262-001-0248-0, vol. 50, no. 12, 1 February 2002 (2002-02-01), pages 673 - 681, XP002236556, ISSN: 0340-7004 *
JAGER E ET AL: "Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, UNITED STATES LNKD- DOI:10.1084/JEM.187.2.265, vol. 187, no. 2, 19 January 1998 (1998-01-19), pages 265 - 270, XP002477113, ISSN: 0022-1007 *
JOOEUN BAE ET AL: "Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, 15 February 2005 (2005-02-15), pages 1629 - 1638, XP007912765, ISSN: 1078-0432 *
WITTMAN VAUGHAN P ET AL: "Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 177, no. 6, 1 September 2006 (2006-09-01), pages 4187 - 4195, XP002514758, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
CA2656583A1 (fr) 2007-12-13
AU2007254859A1 (en) 2007-12-13
WO2007143104A2 (fr) 2007-12-13
IL195470A0 (en) 2011-08-01
WO2007143104A8 (fr) 2008-07-31
EP2026837A2 (fr) 2009-02-25

Similar Documents

Publication Publication Date Title
IL195470A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
IL179427A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
HK1200846A1 (en) High affinity human antibodies to human il-4 receptor il-4
IL196322A0 (en) Improved process for the culturing of cells
EP1988152A4 (fr) Construction pour la culture cellulaire, contenant pour la culture cellulaire, construction ayant un sphéroïde, contenant ayant un sphéroïde et procédé de production correspondant
IL207449A0 (en) Genetically modified cyanobacteria, methods of producing the same and methods of producing ethanol utilizing the same
HK1137483A1 (zh) 修飾抗體的方法和具有改善的功能性質的修飾抗體
ZA201003876B (en) Antibodies to gdf8 as uses thereof
HK1194395A1 (zh) 抗體及其製備和使用方法
EP2334330A4 (fr) Anticorps anti-cd147, procédés, et utilisations
HK1156326A1 (en) Anti-hepcidin-25 selective antibodies and uses thereof
EP2162531A4 (fr) Procédé et moyens pour cultiver des ostéoblastes
EP2262834A4 (fr) Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d utilisation
IL190014A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
GB0600991D0 (en) Assays, antibodies and uses thereof
AU2007905553A0 (en) Process for the production of P2X7 antibodies and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17P Request for examination filed

Effective date: 20090202

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RECEPTOR LOGIC INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WEIDANZ, JON, A.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100507

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/40 20060101ALI20100429BHEP

Ipc: C07K 16/32 20060101ALI20100429BHEP

Ipc: C07K 16/30 20060101ALI20100429BHEP

Ipc: C07K 16/28 20060101ALI20100429BHEP

Ipc: C07K 16/26 20060101ALI20100429BHEP

Ipc: C07K 16/18 20060101ALI20100429BHEP

Ipc: C07K 14/74 20060101ALI20100429BHEP

Ipc: C12P 21/06 20060101ALI20100429BHEP

Ipc: C07H 21/04 20060101ALI20100429BHEP

Ipc: A61K 39/00 20060101AFI20080225BHEP

17Q First examination report despatched

Effective date: 20111115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140103